ZytoVision GmbH of Bremerhaven at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

ZytoVision GmbH

Fischkai 1, 27572 Bremerhaven
Germany
Telephone +49 471 4832300
Fax +49 471 4832509
info@zytovision.com

This company is co-exhibitor of
DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg e.V.

Hall map

MEDICA 2018 hall map (Hall 3): stand G60

Fairground map

MEDICA 2018 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.04  Other molecular diagnostics testing

Our products

Product category: Other molecular diagnostics testing

Method Description - ZytoFast®

The ZytoFast® system uses oligonucleotide probes tagged with Biotin which are detected using enzyme-conjugated streptavidin targeting the tag. The enzymatic reaction of chromogenic substrates, e.g. BCIP/NBT or AEC, leads to the formation of strong color precipitates that can be visualized by light microscopy.

More Less

Product category: Other molecular diagnostics testing

Method Description - ZytoFast® PLUS

The ZytoFast® PLUS system uses Digoxigenin-labeled probes which are detected using primary antibodies. These antibodies are detected by polymerized enzyme-conjugated secondary antibodies. The enzymatic reaction of chromogenic substrates, e.g. NBT/BCIP, AEC or DAB, leads to the formation of strong color precipitates that can be visualized by light microscopy.

More Less

Product category: Other molecular diagnostics testing

ZytoFast ® EBV Probe

The ZytoFast EBV-CISH System is designed for the detection of Epstein-Barr virus (EBV) RNA in paraffin-embedded tissue sections or cell samples. EBV is a member of the gamma-herpesvirus group and one of the most common viruses in humans. Transmission of EBV requires close, intimate contact with a person excreting the virus in its saliva. EBV is the etiological agent of infectious mononucleosis and has been implicated in the pathogenesis of an increasing number of human malignancies such as Burkitt’s lymphoma, nasopharyngeal carcinoma, and polyclonal lymphomas.

More Less

About us

Company details

It all started with a vision: to develop and produce innovative in vitro diagnostic products, primarily for tumour diagnosis, based on the technique of in situ hybridization. That vision has since become reality, with the result that the name »ZytoVision« is identified the world over with technological and cost leadership in this field.

Our company – a privately managed enterprise based in Bremerhaven, Germany – has been operating successfully in the international market for more than 10 years and is widely regarded as a pioneer in high-quality diagnostic devices. More than 50 employees are working continuously to develop, improve, produce and package our products. And we are steadfast in our goal of ensuring that our product portfolio is always complete and up-to-date in our core areas of solid and haematological tumour diagnostics. Our more than 250 CE-certified IVDs (in vitro diagnostic devices) are already being used in more than 60 countries around the world.

More Less